Home Newsfeeds Raymond James Initiates Coverage On Avidity Biosciences with Strong Buy Rating, Announces Price Target of $29

Raymond James Initiates Coverage On Avidity Biosciences with Strong Buy Rating, Announces Price Target of $29

Raymond James analyst Steven Seedhouse initiates coverage on Avidity Biosciences (NASDAQ:RNA) with a Strong Buy rating and announces Price Target of $29.

byBenzinga Newsdesk

July 12, 2022

1 minute read

Raymond James analyst Steven Seedhouse initiates coverage on Avidity Biosciences (NASDAQ:RNA) with a Strong Buy rating and announces Price Target of $29.

Benchmark Initiates Coverage On Magnite with Buy Rating, Announces Price Target of $18

By Benzinga Newsdesk

July 14, 4:55 AM

Benchmark analyst Daniel Kurnos initiates coverage on Magnite (NASDAQ:MGNI) with a Buy rating and announces Price Target of $18.

MGNI

McDonald’s Revenues Expected To Increase, Plus Merck And More On CNBC’s ‘Final Trades’

By Avi Kapoor

January 4, 10:11 AM

On CNBC’s "Halftime Report Final Trades," Joseph Terranova of Virtus Investment Partners named Merck & Co., Inc. (NYSE: MRK)

MCD

Williams-Sonoma Gets A Big Downgrade, Analyst Calls It ‘Poster Child’ Retailer That Benefited During The Pandemic

By Anusuya Lahiri

October 25, 11:05 AM

Jefferies analyst Jonathan Matuszewski downgraded Williams-Sonoma, Inc (NYSE:WSM) from Hold to Underperform and cut the price target from $160 to $100. As…

WSM